<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03052400</url>
  </required_header>
  <id_info>
    <org_study_id>16-04-2482</org_study_id>
    <nct_id>NCT03052400</nct_id>
  </id_info>
  <brief_title>Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety&#xD;
      of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated&#xD;
      with Cushing's syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double blind, placebo-controlled clinical trial examining the efficacy and safety&#xD;
      of mifepristone 600 mg daily in male subjects with type 2 diabetes mellitus, not associated&#xD;
      with Cushing's syndrome, and sub-optimally controlled on basal insulin, with or without&#xD;
      prandial insulin and/or maximally-tolerated doses of metformin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    End of Funding&#xD;
  </why_stopped>
  <start_date type="Actual">February 3, 2017</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>3 months</time_frame>
    <description>Glycemic lowering</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>3 months</time_frame>
    <description>Weight in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>3 months</time_frame>
    <description>BMI in kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage total body fat mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lean body mass</measure>
    <time_frame>3 months</time_frame>
    <description>Percentage total body lean mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>3 months</time_frame>
    <description>HOMA and OGTT dynamic measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipids</measure>
    <time_frame>3 months</time_frame>
    <description>Fasting lipids and lipoproteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Systolic and diastolic BP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic events</measure>
    <time_frame>3 months</time_frame>
    <description>Symptomatic mild and severe hypoglycemic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Non-hypoglycemia-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin dose</measure>
    <time_frame>3 months</time_frame>
    <description>Total daily insulin dosage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Mifepristone 600 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone 600 mg daily</intervention_name>
    <description>Glucocorticoid receptor antagonist</description>
    <arm_group_label>Mifepristone 600 mg daily</arm_group_label>
    <other_name>Korlym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Males&#xD;
&#xD;
          -  Age 18-65 inclusive&#xD;
&#xD;
          -  Established T2DM for ≥ 1 year&#xD;
&#xD;
          -  Taking stable doses (≤ 20% change in total daily insulin dose within 2 months prior to&#xD;
             screening) of basal insulin, with or without prandial insulin (total daily dose must&#xD;
             be ≤ 200 units)&#xD;
&#xD;
          -  Baseline hemoglobin A1c (HbA1c) 8.0%-10.5%&#xD;
&#xD;
          -  No use of any anti-hyperglycemic agents (oral or injectable) other than metformin or&#xD;
             insulin&#xD;
&#xD;
          -  No history or clinical suspicion of type 1 diabetes mellitus&#xD;
&#xD;
          -  No concurrent chronic use of any corticosteroids by any route and for any indication,&#xD;
             or concurrent conditions that may require the initiation of glucocorticoids during the&#xD;
             study&#xD;
&#xD;
          -  No concurrent lipid-lowering medications whose levels are dependent on CYP3A pathway&#xD;
             clearance (e.g., simvastatin, lovastatin, atorvastatin, fluvastatin and rosuvastatin)&#xD;
             should either be washed out for at least one month prior to enrollment and/or switched&#xD;
             to alternative LDL-cholesterol lowering agents (e.g., pravastatin or ezetimibe) for at&#xD;
             least one month.&#xD;
&#xD;
          -  No contraindications or known intolerance to mifepristone&#xD;
&#xD;
          -  No concurrent use of strong CYP3A inhibitors (e.g., cyclosporine, ergotamine,&#xD;
             fentanyl, quinidine, sirolimus, tacrolimus, imidazole antifungals, HIV protease&#xD;
             inhibitors, certain macrolide antibiotics)&#xD;
&#xD;
          -  No concurrent use of CYP3A inducers (e.g., phenytoin, phenobarbital, carbamazepine,&#xD;
             rifampin)&#xD;
&#xD;
          -  No concurrent use of medications that may prolong the QT interval (e.g., selected&#xD;
             antipsychotics and antidepressants, quinolone antibiotics)&#xD;
&#xD;
          -  No daily use of warfarin or non-steroidal anti-inflammatory agents&#xD;
&#xD;
          -  Baseline K+ and Mg+2 within the laboratory normal ranges, with or without oral K+&#xD;
             and/or Mg+2 supplementation&#xD;
&#xD;
          -  Fasting plasma glucose (FPG) averaging &lt; 280 mg/dL and without polyuria or polydipsia&#xD;
&#xD;
          -  No symptomatic hypoglycemia averaging &gt; once per day&#xD;
&#xD;
          -  Able and willing to perform self-monitoring of blood glucose (SMBG)&#xD;
&#xD;
          -  Mean BP &lt; 140 mmHg systolic or 90 mm Hg diastolic&#xD;
&#xD;
          -  Baseline LDL-cholesterol &lt; 200 mg/dL if on lipid-lowering therapy or &lt; 250 mg/dL while&#xD;
             not on lipid-lowering therapy&#xD;
&#xD;
          -  Fasting triglycerides ≤ 500 mg/dL if on lipid-lowering therapy&#xD;
&#xD;
          -  HDL-cholesterol ≥ 25 mg/dL&#xD;
&#xD;
          -  No known history of prostate cancer, or elevated level of prostate-specific antigen&#xD;
             (PSA) at screening&#xD;
&#xD;
          -  Estimated GFR ≥ 30 mL/min&#xD;
&#xD;
          -  No concurrent endocrinopathies that have not been stabilized with replacement or other&#xD;
             definitive therapies (including known adrenal insufficiency regardless of replacement&#xD;
             therapy, cortisol &lt; 5 μg/dL at screening)&#xD;
&#xD;
          -  No active hemolytic anemias or hemoglobin variants that render the measurement of&#xD;
             HbA1c potentially unreliable&#xD;
&#xD;
          -  No other clinically significant hepatic, cardiovascular (including known personal or&#xD;
             family history of, or risk factors for long-QT syndrome, QTcF prolongation on ECG &gt;&#xD;
             500 ms), infectious (including HIV or any viral hepatitis), inflammatory, neoplastic&#xD;
             or other systemic disease that may contraindicate the change of lipid-lowering&#xD;
             therapy, renders mifepristone unsafe, or otherwise confounds data interpretation&#xD;
&#xD;
          -  Subjects not likely to start other drugs that may influence the study's outcomes&#xD;
             (e.g., weight loss agents)&#xD;
&#xD;
          -  Subjects who are able and willing to comply with all components of the study protocol,&#xD;
             attend all scheduled follow-up visits, or who do not present other foreseeable&#xD;
             barriers that might make the implementation of the protocol problematic or confound&#xD;
             data interpretation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley H Hsia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University of Medicine and Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University of Medicine and Science</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>Stanley Hsia</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>mifepristone</keyword>
  <keyword>glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data sharing as per NIH funding requirements</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

